Alzheimer?s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs

• Type: Another Publication in an International Scientific Journal
• Date: 2023

Authors

Monteiro, AR (Author) Other; Barbosa, DJ (Author) Other; Fernando Remiao (Author) FFUP; Silva, R (Author) Other

Journal

Title: Biochemical Pharmacology

Vol. 211

ISSN: 0006-2952

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00Y-7VC

DOI: 10.1016/j.bcp.2023.115522

Abstract (EN): Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases that affect millions of people worldwide, with both prevalence and incidence increasing with age. It is characterized by cognitive decline associated, specifically, with degeneration of cholinergic neurons. The problem of this disease is even more fundamental as the available therapies remain fairly limited and mainly focused on symptoms' relief. Although the aetiology of the disease remains elusive, two main pathological hallmarks are described: i) presence of neurofibrillary tangles formed by unfolded protein aggregates (hyperphosphorylated Tau protein) and ii) presence of extracellular aggregates of amyloid-beta peptide. Given the complexity surrounding the pathogenesis of the disease, several potential targets have been highlighted and interrelated upon its progression, such as oxidative stress and the accumulation of metal ions. Thus, advances have been made on the development of innovative multitarget therapeutical compounds to delay the disease progression and restore cell function. This review focuses the ongoing research on new insights and emerging disease-modifying drugs for AD treatment. Furthermore, classical and novel potential biomarkers for early diagnosis of the disease, and their role in assisting on the improvement of targeted therapies will also be approached.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14